We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Luminex (LMNX) Q4 Earnings Miss Estimates, Revenues Beat
Read MoreHide Full Article
Luminex Corporation reported fourth-quarter 2020 earnings per share (EPS) of 1 cent, missing the Zacks Consensus Estimate by 92.9%. The bottomline also fell 85.7% year over year.
For 2020, EPS came in at 32 cents, also lagging the Zacks Consensus Estimate by 27.3%. However, the company reported a loss per share of 9 cents in the year-ago period.
Revenues
For the fourth quarter, revenues summed $111.4 million, beating the Zacks Consensus Estimate by 0.4%. The top line also improved 23% on a year-over-year basis.
For the full year, revenues came at $417.4 million, beating the Zacks Consensus Estimate by 1.8%.The topline also rose 25% year over year.
Segmental Analysis
For the fourth quarter, total sample-to-answer molecular diagnostics revenues grew 49% from the prior-year quarter.
System Sales
Revenues at this segment totaled $23.8 million, up 14% from the year-ago quarter.
Consumable Sales
This segment accounted for $12.9 million of revenues, up 11% year over year.
Royalty Revenues
Royalty revenues totaled $13.9 million, up 3% on a year-over-year basis.
Assay Revenues
This segment reported revenues worth $51.3 million, up 41% on a year-over-year basis.
Service Revenues
Revenues in the segment amounted to $6.3 million, up 12% from the year-ago quarter.
Other
Other revenues came in at $3.1 million, up 28% from the prior-year quarter.
Financial Update
The company exited the fourth quarter with cash and cash equivalents of $309.4 million, up from $308.5 millionon a sequential basis.
Cumulative net cash provided by operating activities at the end of the fourth quarter of 2020 came in at $49.9 million compared with $13.5 million in the year-ago period.
Luminex Corporation Price, Consensus and EPS Surprise
Gross profit in the reported quarter was $64.4 million, up 29.2% year over year. Gross margin was 57.9%, expanding 275 basis points (bps).
The company reported adjusted operating profit of $13.4 million, up 130% from the year-ago quarter’s figure. Adjusted operating margin came in at 12%, expanding 560 bps.
Guidance
Revenues for 2021 are reaffirmed to be around $480 million, indicating growth of more than 15% from Luminex's reported 2020 tally. The Zacks Consensus Estimate for the same is pegged at $476.2 million.
Wrapping Up
Luminex exited the fourth quarter on a mixed note. Revenues at each operating segment improved in the quarter. Also, the company continues to gain from its flagship ARIES and VERIGENE platforms that currently have a strong customer base.Further, it witnessed total sample-to-answer molecular diagnostics revenue growth in the quarter. Expansion of both margins is a positive too. Notably the FDA’s Emergency Use Authorization (EUA) for the ARIES SARS-CoV-2 Assay continues to instill optimism on the stock.
However, the plunge in the bottomline is concerning.
Zacks Rank and Other Key Picks
Currently, Luminex carries a Zacks Rank #2 (Buy).
Some other top-ranked stocks in the broader medical space that already announced quarterly results are Hologic, Inc. (HOLX - Free Report) , Abbott Laboratories (ABT - Free Report) and AngioDynamics, Inc. (ANGO - Free Report) . While Hologic sports a Zacks Rank #1 (Strong Buy), the other two presently carry the same Zacks Rank as Luminex.You can see the complete list of today’s Zacks #1 Rank stocks here.
Hologic reported first-quarter fiscal 2021 adjusted EPS of $2.86, which surpassed the Zacks Consensus Estimate by 33.6%.
Abbott reported fourth-quarter 2020 adjusted EPS of $1.45, which surpassed the Zacks Consensus Estimate by 6.6%. Further, fourth-quarter worldwide sales of $10.7 billion outpaced the consensus mark by 7.9%.
AngioDynamics reported second-quarter fiscal 2021 adjusted EPS of a penny. The Zacks Consensus Estimate was of a loss per share of 2 cents. Additionally, revenues of $72.8 million beat the consensus mark by 8%.
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 77 billion devices by 2025, creating a $1.3 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 4 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2022.
Image: Bigstock
Luminex (LMNX) Q4 Earnings Miss Estimates, Revenues Beat
Luminex Corporation reported fourth-quarter 2020 earnings per share (EPS) of 1 cent, missing the Zacks Consensus Estimate by 92.9%. The bottomline also fell 85.7% year over year.
For 2020, EPS came in at 32 cents, also lagging the Zacks Consensus Estimate by 27.3%. However, the company reported a loss per share of 9 cents in the year-ago period.
Revenues
For the fourth quarter, revenues summed $111.4 million, beating the Zacks Consensus Estimate by 0.4%. The top line also improved 23% on a year-over-year basis.
For the full year, revenues came at $417.4 million, beating the Zacks Consensus Estimate by 1.8%.The topline also rose 25% year over year.
Segmental Analysis
For the fourth quarter, total sample-to-answer molecular diagnostics revenues grew 49% from the prior-year quarter.
System Sales
Revenues at this segment totaled $23.8 million, up 14% from the year-ago quarter.
Consumable Sales
This segment accounted for $12.9 million of revenues, up 11% year over year.
Royalty Revenues
Royalty revenues totaled $13.9 million, up 3% on a year-over-year basis.
Assay Revenues
This segment reported revenues worth $51.3 million, up 41% on a year-over-year basis.
Service Revenues
Revenues in the segment amounted to $6.3 million, up 12% from the year-ago quarter.
Other
Other revenues came in at $3.1 million, up 28% from the prior-year quarter.
Financial Update
The company exited the fourth quarter with cash and cash equivalents of $309.4 million, up from $308.5 millionon a sequential basis.
Cumulative net cash provided by operating activities at the end of the fourth quarter of 2020 came in at $49.9 million compared with $13.5 million in the year-ago period.
Luminex Corporation Price, Consensus and EPS Surprise
Luminex Corporation price-consensus-eps-surprise-chart | Luminex Corporation Quote
Margins
Gross profit in the reported quarter was $64.4 million, up 29.2% year over year. Gross margin was 57.9%, expanding 275 basis points (bps).
The company reported adjusted operating profit of $13.4 million, up 130% from the year-ago quarter’s figure. Adjusted operating margin came in at 12%, expanding 560 bps.
Guidance
Revenues for 2021 are reaffirmed to be around $480 million, indicating growth of more than 15% from Luminex's reported 2020 tally. The Zacks Consensus Estimate for the same is pegged at $476.2 million.
Wrapping Up
Luminex exited the fourth quarter on a mixed note. Revenues at each operating segment improved in the quarter. Also, the company continues to gain from its flagship ARIES and VERIGENE platforms that currently have a strong customer base.Further, it witnessed total sample-to-answer molecular diagnostics revenue growth in the quarter. Expansion of both margins is a positive too. Notably the FDA’s Emergency Use Authorization (EUA) for the ARIES SARS-CoV-2 Assay continues to instill optimism on the stock.
However, the plunge in the bottomline is concerning.
Zacks Rank and Other Key Picks
Currently, Luminex carries a Zacks Rank #2 (Buy).
Some other top-ranked stocks in the broader medical space that already announced quarterly results are Hologic, Inc. (HOLX - Free Report) , Abbott Laboratories (ABT - Free Report) and AngioDynamics, Inc. (ANGO - Free Report) . While Hologic sports a Zacks Rank #1 (Strong Buy), the other two presently carry the same Zacks Rank as Luminex.You can see the complete list of today’s Zacks #1 Rank stocks here.
Hologic reported first-quarter fiscal 2021 adjusted EPS of $2.86, which surpassed the Zacks Consensus Estimate by 33.6%.
Abbott reported fourth-quarter 2020 adjusted EPS of $1.45, which surpassed the Zacks Consensus Estimate by 6.6%. Further, fourth-quarter worldwide sales of $10.7 billion outpaced the consensus mark by 7.9%.
AngioDynamics reported second-quarter fiscal 2021 adjusted EPS of a penny. The Zacks Consensus Estimate was of a loss per share of 2 cents. Additionally, revenues of $72.8 million beat the consensus mark by 8%.
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 77 billion devices by 2025, creating a $1.3 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 4 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2022.
Click here for the 4 trades >>